Aurora Cannabis To Launch Cogent International’s New CBD Lozenge On Its Medical Marijuana Patient Platform

Canadian medical marijuana giant Aurora Cannabis Inc. (NASDAQ:ACB) (TSX:ACB) partnered with Cogent International Manufacturing Ltd., a subsidiary of wellness innovator Vectura Fertin Pharma Inc. Under this commercial collaboration, Cogent will initially launch its newly developed CBD lozenge on Aurora’s Canadian medical marijuana patient platform, providing access to patient feedback that will be used to validate the product proposition and patient responses while building real-world patient data for future analysis.

“We are excited about this commercial collaboration that will allow Aurora to leverage its industry-leading patient platform in Canada to support advancements in medical cannabis, as well as to provide our patients with access to Vectura Fertin Pharma’s new CBD lozenge,” stated Miguel Martin, CEO of Aurora. “As a global leader in the manufacturing of pharmaceutical-grade medical cannabis, we are pleased to see increased interest in the possibilities of medical cannabis as part of healthcare options made available to Canadians.”

The news …

Full story available on Benzinga.com